

Quality of Life in Pediatric Cancer Patients

ABSTRACT

Background: In recent years the survival rates for children diagnosed with cancer has increased as result of successful treatment. Evaluation of health related quality of life during the process of treatments is important for recognition of acute dysfunction related to therapy and disease. **Aim** of the study is to identify the health-related quality of life in pediatric cancer patients and to detect the potential predictors of a total quality of life and its domains. **Material and Methods:** It is a cross-sectional study done on convenient sample of pediatric cancer patients. Their diagnosis was confirmed at pediatric hematology clinic and day care unit at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

Results: a total number of 51 children participated in this study, their age ranging from 8-15 years with mean 10.15 ± 2.52 . Hematological malignancies represented 70.5% of the sample, with the highest percentage for acute lymphocytic leukemia (45%). The mean value of total quality of life is 73.48. The best scores of subscales were cognitive problems (92.54), communication (82.67), and nausea (76.86), otherwise poorer score was detected. Although the value of total quality of life was relatively good however visiting the hospital more than 3 times per month, male gender, duration of therapy and duration of diagnosis more associated with more pain and hurt, great worry and treatment anxiety. So, our **conclusion:** an early and continuous evaluation of these factors can supply the essential for interventions to enhance response to treatment.

Key Words: Health-related quality of life; QOL; cancer; children.

30 **1. INTRODUCTION**

31

32 In recent years the survival rates for children diagnosed with cancer has increased as
33 result of successful treatment. However, many studies reported that these treatments take part in
34 the formation of physical and psychosocial weakness for cancer survivors [1].

35

36 Globally, the incidence of cancer in children differs from 48 to 70 per million children
37 less than 15 years of age [2]. The incidence of childhood cancer in some developed countries,
38 such as in United State, Ireland, Switzerland, and in Australia has reported with rates of 15.3, 13,
39 13.5, and 16 per 100,000 children, respectively, however in Asia the data are generally lower [3-
40 11].

41

42 In Saudi Arabia cancer in children about 8% of total cancer cases. The greatest prevalent
43 cancers were leukemia (34.1%), lymphoma (15.2%), brain (12.4%), and kidney cancers (5.3%)
44 [12].

45

46 Concerning the children with cancer, evaluation of health related quality of life (QOL)
47 during the process of treatments is important for recognition of acute dysfunction related to
48 therapy and disease, in addition, to assessing predicted remaining dysfunction in long-term
49 survivors [13,14]. Health related QOL targets a variation of aspects covering physical, mental
50 and social areas [15].

51

52 Despite the enhanced survival statistics, malignancy in children remains a life-threatening
53 condition, and act as a great challenge to both child and family. During treatment course, most
54 children experience disagreeable physical adverse-effects [16].

55

56 This study designed to identify the health-related quality of life in childhood cancer patients
57 and to detect the relationship between disease, treatment, and sociodemographic factors with the
58 total quality of life and its subscales. Additionally, to detect the potential predictors of a total
59 quality of life and its subscales. To our knowledge, no similar study was found in search engine
60 at Jeddah

61

62 **2. MATERIAL AND METHODS**

63 **2.1 Study Design, Sampling and sitting**

64 This study is a cross-sectional study and conducted on a convenient sample of
65 pediatric cancer patients (We enrolled all cancer patients who came to the hospital from April to
66 November ,2018). Their diagnosis was confirmed at pediatric hematology clinic and day care
67 unit at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. Our inclusion
68 criteria of the study including children 8-15 years of age, diagnosed with cancer for more than
69 one month, and receiving cancer treatments during the time of data collection. Data collected by
70 interviewing questionnaire. Ethical approval was obtained from the Institutional Review
71 Board/Ethics Committee and informed consent taken from all parents of children in the study.

72

73 **2.2 Study tool**

74 Data collection tool is the Pediatric Quality of Life Cancer Module (PedsQL™ 3.0) [17],
75 in addition to sociodemographic information. We used the Arabic version after taking consent
76 from the authors, the study tool is valid and reliable [17-19]. It is intended to measure health
77 related QOL domains specifically for pediatric cancer. It includes 8 fields with the entire of 27
78 items for the whole module; pain and hurt include 2 items, procedural anxiety, treatment anxiety,
79 worry, perceived physical appearance, and communication, each one of them includes 3 items,
80 whereas nausea and cognitive problems include 5 items for each [14].

81

82 Each item of the instrument is consisting of a 5-point Likert scale (0 = never a problem; 1
83 = almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = almost always a
84 problem. Then we transformed the scale to an equivalent score from 0 to 100, where 0 denoted
85 the poorest quality of life and 100 denoted the greatest quality of life. The whole QOL is the
86 mean of the scores for all fields, while QOL for each field is the mean of scores of its items.
87 Moreover, we divided the score of whole QOL and fields into two grades, good scale which
88 reflect the good quality of life (> 70) and poor scale (< 70) which reflect the poor quality of life.

89 Procedures associated with treatments: *a) intensity of therapy* ,which divided into three
90 levels, low intensity had a score 1, represented the patients had surgery only and/or six months

91 chemotherapy with a satisfactory prognosis, medium intensity had a score 2 , represented the
92 patients with chemotherapy longer than 6 months with an intermediate prognosis, in addition to
93 high intensity of treatment that referred to treatment according to high risk protocols, bone
94 marrow transplantation, and/or diseases with less satisfactory prediction, it took score 3 [20,21].
95 *b) Rate of hospital visits:* classified into less than or equal to 3 and > 3 visits per month. *c)*
96 *Treatment duration:* low duration represented ≤ 6 months, medium duration from 6 months to 1
97 year, and high duration denoted to ≥ 1 year. *d) Treatment phase:* it divided into two sets, one who
98 is on-treatment (continue getting anticancer treatment) and the other who on the follow-up (cases
99 completed their treatment and planned for interval follow up) [22].

100

101 **2.3 Data Entry and Analysis**

102 The data collected were analyzed using SPSS, version 16. Numerical data denoted by
103 frequency while quantitative data existed as mean, and standard deviation (SD). We used
104 independent sample t-test and analysis of variance (ANOVA) to detect the differences in total
105 and mean subscale scores of the PedsQL3.0 cancer module between the studied variables. Binary
106 logistic regression analysis test used to find out the predictors of total QOL and all subscale. P
107 value < 0.05 was considered significant.

108

109 **3. RESULTS**

110 **3.1 Characters of the study group:**

111 A total number of 51 children participated in this study, 62.7% male and 37.3% female,
112 their age ranging from 8-15 years with mean 10.52; median 8 years and 5.45 as mean family
113 size. About 94.1% of them are non-Saudi and 5.9% are Saudi. 58.8% of children stopped the
114 education, while 41.2% are continuous. Hematological malignancies represented 70.5% of the
115 sample, with the highest percentage for acute lymphocytic leukemia (ALL) (45%). A high
116 proportion of children (60.8%) were visiting the hospital more than 3 times per month. Regarding the
117 type of treatment, most of them (88.2%) on chemotherapy treatment. Low intensity of therapy (54.9%)
118 was more frequent than medium and high intensity (35.3% and 9.8%, respectively). (table 1). In
119 addition, 72.5% of the participants had treatment duration less than one year at the time of data

120 collection with a compliance rate of 98% of the sample. A high frequency of the children's
121 mothers and fathers had educated (84.3% and 90.2%, respectively).

122

123 **3.2 PedsQL 3.0 subscales**

124 Table 2, show mean scores of total health QOL and its subscales among the study
125 group. The value of total health related QOL is 73.48 The best scores of subscales (greater than
126 70) were detected in three out of eight subscales which are cognitive scale (92.54),
127 communication (82.67 and nausea (76.86). while the lowest scores were found in procedural
128 anxiety (60.78) followed by worry (61.76), pain & hurt (65.45) treatment anxiety (66.01) and
129 perceived physical appearance (69.77).

130 **3.3 Association between study group characteristics and PedsQL 3.0 subscales:**

131 The influence of variables on total health related QOL and subscale were demonstrated in
132 table 3. We observed that worry subscale was statistically great among patients visiting the
133 hospitals more than 3 times per month than children visiting less than 3 times ($P=0.03$) and
134 those with duration of diagnosis equal to one year or more in comparison to children with
135 diagnosis duration less than one year ($P= 0.01$). However, pain and hurts statistically increased
136 among male children than female ($P=0.04$). While treatment anxiety was statistically increased
137 among children with duration of therapy equal to 1 year or more ($P=0.03$).

138

139

140 **3.4 Predictors of health-related quality of life in the study group:**

141 The binary logistic regression model represented in table 4 and showing predictors of
142 health related QOL in each subscale. The most common predictors for pain and hurt subscale
143 were gender, age at the time of diagnosis and duration of diagnosis. Males were more likely to
144 have pain and hurt than female (AOR= 8.77), children diagnosed with the disease at age less than
145 7 years are more likely to have pain & hurt than those who diagnosed with cancer at an age equal
146 to 7 years or more (AOR=4.74), and children with duration of diagnosis more than one year are

147 more likely to feel pain and hurt than those with duration of diagnosis less than one year (AOR=
148 8.87), the differences were statistically significant. Children with a medium score of treatment
149 intensity are likely to have more nausea than those with the low and high score (AOR=3.28).
150 moreover, males likely to worry four times more than female (AOR=4.53).

151 4. DISCUSSION

152 Our study reported that the score of total QOL in childhood cancer was 73.48 and
153 seemed to be relatively good may be due to half of the study group had low intensity of therapy,
154 this means good prognosis and short period of chemotherapy; other cause the parents may
155 display passion and love in a trial to get away from the impendence of cancer. Simultaneously,
156 the children promote their own protection, so the effect of the disease onto their QoL may be
157 restricted. This result agrees with some studies done in different countries as United State (US),
158 it was 73.6, 72.2 for the Indonesian, 71.02 for the Chinese mandarin child- hood cancer patients
159 and 72.75 for Lebanon [23-27]. Moreover, our score is better than the results of the Pakistani
160 study [14] which demonstrated a much lower total QOL score of 42.07 and 62.29 in the Egyptian
161 study [1].

162
163 In this study, although the mean value of total heath related QOL was relatively good
164 and similar to the score of some developed countries, however we observed low mean value in
165 pain and hurt; procedural anxiety, treatment anxiety; worry and perceived physical appearance
166 subscales. We did not find any statistically significant effect when the total QOL compared with
167 the social and medical characteristic of study group, maybe due to small sample size. However,
168 in some subscales, we found males experienced significantly more pain and hurt than females
169 and this is compatible with regression model in our results which reported that the most common
170 predictors for pain and hurt subscale were gender, as males feel pain seven times more than
171 females. This result opposite to that reported from Lebanon, Egypt and US, [26, 1, 17], the
172 reason may be due to the differences in study type or methodology or age of the participants. In
173 addition to the gender we found also age at the time of diagnosis and duration of diagnosis (more
174 than one year) were other predictors for pain & hurt and this like other study [13].

175
176 Additionally, we reported children with a duration of therapy more than one year suffer
177 more treatment anxiety, may be due to high frequency of visiting the hospital and long duration

178 of treatment or may have experience more pain during the procedures, this is in agreement with
179 the results of Canadian and Lebanon studies [27,26].

180 Furthermore, great worry increased in children visiting the hospital more than three
181 times per month and those with duration of therapy more than one year. such findings indicated
182 more frequent exposure to hospital atmosphere and subsequently more therapy administration could be a
183 leading reason. This results consistence with other results [13,1].

184
185 We observed that Children with a medium score of treatment intensity are likely to have
186 more nausea than those with a low score, the explanation may be the medium intensity of
187 treatment represents the cases treated with chemotherapy longer than six months according to the
188 treatment protocol so they have more nausea than a lower score treatment which represents the
189 surgery only and/or six months chemotherapy and this in agreement with results of some studies
190 [1,13,28].

191

192 **5.CONCLUSION AND RECOMMENDATION:**

193 In this study although the total health related QOL was relatively good however high
194 frequency of visiting the hospital, male gender and long duration of therapy and increased
195 treatment intensity are associated with poor QOL in the subscales among childhood cancer
196 patients. So, an early and continuous evaluation of these factors and predictors can supply the
197 essential for interventions to enhance response to treatment and detection of children at risk of
198 poor QOL during and after treatment. We recommend another studies in the same context and
199 containing large number of children.

200

201 **LIMITATION**

202 This study includes some limitation like dependence on mothers' evaluations of their
203 child's QOL. Although most of study group were older but there was a difficulty to asking them
204 directly as they tended to be too ill to respond. In addition, we depend more on the mothers than
205 fathers as because she tends to be more contact and care with the child during the period of
206 disease and treatment. They more responsible for everything as medication, treatment and more
207 likely to stay in the hospital with the child. This may influence parent's perception of child's

208 QOL. Others have noted that the multiple different perspectives of QOL including the parent
209 perspective are all important and contribute to our understanding of child health [29]. Although
210 our sample was convenient, but we recruited all children visited the hospital during that period.
211
212

213 **LIST OF ABBREVIATION**

214 ALL: Acute Lymphocytic Leukemia
215 ANOVA: Analysis of Variance
216 AOR: Adjusted Odds Ratio
217 KAUH: King Abdulaziz University Hospital
218 PedsQL 3.0: Pediatric Quality of Life Inventory™ 3.0 Cancer Module
219 QOL: quality of life
220 SD: Standard Deviation
221 SPSS: Statistical Package for the Social Sciences
222 US: United State
223
224
225

226 **COMPETING INTERESTS**

227 The authors declared that they have no competing interests.
228
229
230

231 **CONSENT**

232 Informed consent taken from all parents of children in the study with the guide lines of ethical
233 committee .

234 **ETHICAL APPROVAL**

235 Ethical approval was obtained from the Institutional Review Board/Ethics Committee at Faculty
236 of Medicine, King Abduaziz University.

237
238
239
240

241

242 **Table 1: Demographic and medical characteristics of the study group.**

Variable	Frequency (n=51) n (%)
Age /year	
Mean \pm SD	10.15 \pm 2.52
Rang	8-15
Median	8
Gender:	
Male	32 (62.7)
Female	19 (37.3)
Nationality:	
Saudi	3 (5.9)
Non-Saudi	48 (94.1)
Educational Status:	
Continuous:	21 (41.2)
Stopped	30 (58.8)
Type of malignancy:	
Hematological:	36 (70.5)
ALL (Acute Lymphoblastic Leukemia)	23 (45.0)
AML = Acute Myeloid Leukemia	5 (9.8)
chronic myeloid leukemia	1 (2.0)
HD = Hodgkin Lymphoma	4 (7.8)
NHD= non-Hodgkin lymphoma	3 (5.9)
Solid:	15 (29.5)
Brain tumor	6 (11.7)
Nephroblastoma	1 (2.0)
Skin cancer	1 (2.0)
Ewing's sarcoma	5 (9.8)
Adenocarcinoma	1 (2.0)
Malignant neoplasm of parotid gland	1 (2.0)
Hospital visits:	
Three times or less/ month	20 (39.2)
More than three times /month	31 (60.8)
Type of treatment:	
Chemotherapy	45 (88.2)
Radiotherapy	2 (3.9)
Surgical	4 (7.8)
Intensity of therapy:	
Low	28 (54.9)
Medium	18 (35.3)
High	5 (9.8)
Treatment phase:	
On-treatment	31 (60.8)
Follow up	20 (39.2)

243 ALL (Acute Lymphoblastic Leukemia), AML = Acute Myeloid Leukemia

244 chronic myeloid leukemia , HD = Hodgkin Lymphoma, NHD= non-Hodgkin lymphoma

245

246 **Table 2: Mean scores of total health QOL and its subscales among study group.**

247

Scale / subscale	No of items	Mean	Std. Deviation	Median
Total Quality of life		73.48	15.78	77.60
Pain & hurt	2	65.45	25.58	70.50
Nausea	5	76.86	24.69	90.00
Procedural Anxiety	2	60.78	34.85	66.66
Treatment Anxiety	3	66.01	33.41	75.00
Worry	3	61.76	30.51	66.66
Cognitive Problem	5	92.54	14.36	100.00
Perceived Physical appearance	3	69.77	27.02	75.00
Communication	3	82.67	28.52	100.00

248

249

250

251

252

253

254

255

256

257

259 Table 3: Association between study variables with total QOL and its subscales.

	Total QOL	Pain & Hurts	Nausea	Procedural Anxiety	Treatment Anxiety
Age at diagnosis:					
<7 years (n=18)	72.30±15.18	84.02±29.01	80.83±18.96	57.87±34.82	62.03±32.36
≥ 7 years (n=33)	74.12±16.30	73.86± 29.70	74.69±27.35	62.37±35.30	61.61±29.96
t test	-0.38	1.18	0.94	-0.46	-0.48
P value	0.69	0.24	0.35	0.66	0.63
Gender:					
Male (n=32)	75.26±15.50	71.87±33.89	77.65±21.92	63.28±34.96	70.57±32.16
Female (n=19)	70.49±16.22	86.84±17.41	75.52±29.38	56.57±35.19	58.33±34.91
t test	1.04	2.07	0.29	0.66	1.27
P value	0.30	0.04*	0.76	0.51	0.20
Family size:					
≤ 5 children (n=28)	73.63±15.87	81.25±26.24	76.07±27.05	63.09±33.44	63.69±35.73
> 5 children (n= 23)	73.30±16.03	72.82±33.21	77.82±22.04	57.97±37.05	68.84±30.89
t test	0.07	1.01	-0.25	0.51	-0.54
P value	0.94	0.31	0.80	0.60	0.58
Hospital visits:					
≤ 3 times/ month (n=20)	71.19±16.07	80.00±29.63	77.75±24.35	56.25±34.50	60.00±31.36
>3 times / month (n=31)	74.95±15.68	75.80±29.91	76.29±25.29	63.70±35.32	69.89±34.60
t-test	-0.82	0.49	0.20	-0.74	-1.03
P value	0.41	0.62	0.83	0.46	0.30
Type of treatment:					
Chemotherapy (n=45)	72.83±15.84	76.38±29.70	75.44±25.10	58.70±34.81	65.37±33.84
Radiotherapy (n=2)	81.19±2.87	56.25±44.19	77.50±31.81	70.83±41.24	75.00±35.35
Surgical (n=4)	76.92±20.13	1.00±0.00	92.50±15.00	79.16±36.32	68.75±36.24
F test	0.36	1.75	0.87	0.71	0.09
P value	0.69	0.18	0.42	0.49	0.91
Duration of diagnosis:					
≤ 6 months (n=24)	70.39±17.24	72.39±32.96	73.75±24.41	65.27±31.81	64.23±33.28
> 6 months (n=7)	85.00±8.19	85.71±24.39	77.85±27.21	63.09±40.78	90.47±12.19
≥ 1 year (n=20)	73.16±14.61	80.62±27.04	80.25±24.99	54.58±37.11	59.58±35.79
F test	2.46	0.73	0.37	0.52	2.40
P value	0.09	0.48	0.68	0.59	0.10
Therapy duration:					
≤ 6 months (n=32)	72.35±16.59	73.82±33.05	75.62±22.99	63.02±33.12	67.70±32.70
> 6 months(n=5)	81.56±6.98	82.50±24.36	89.00±11.40	53.33±39.79	91.66±11.78
≥ 1 year (n=14)	73.18±16.07	83.92±22.16	75.35±31.34	58.33±39.08	52.97±35.44
F test	0.73	0.63	0.66	0.20	2.76
P value	0.48	0.53	0.52	0.81	0.03*

Intensity of treatment:					
Low (n=28)	72.12±17.53	76.78±30.37	76.42±23.48	62.20±34.43	68.45±31.12
Medium (n=18)	73.61±14.46	79.16±30.01	74.16±27.87	57.87±35.29	58.33±38.87
High (n=5)	80.66±8.49	75.00±29.31	89.00±19.49	63.33±42.73	80.00±20.91
F test	0.61	0.05	0.70	0.09	0.98
P value	0.54	0.94	0.49	0.90	0.38
Treatment phase:					
On-treatment (n=30)	73.69±16.72	75.40±31.37	74.67±24.66	64.78±33.31	70.16±31.6
Follow-up (n=21)	73.16±14.61	80.62±27.04	80.25±24.99	54.58±37.11	59.58±35.79
t-test	0.11	0.61	0.78	1.02	1.10
P value	0.90	0.54	0.43	0.31	0.27

260 ≤ = less than or equal to

> = More than

* = significant (p< 0.05)

261

262

263

264 **Continue table 3: Association between study variables with total QOL and its subscales.**

Variables	Worry	Cognitive Problem	Perceived Physical appearance	Communication
Age at diagnosis:				
< 7 years (18)	62.03±32.36	91.38±14.93	64.35±27.23	75.00±31.95
≥ 7 years (33)	61.61±29.96	93.18±14.24	72.72±26.86	86.86±26.02
t test	0.04	-0.42	-1.05	-1.43
P value	0.69	0.67	0.29	0.15
Gender:				
Male (n=32)	66.92±30.26	95.00±8.13	73.17±25.37	83.59±29.59
Female (n=19)	53.07±29.68	88.42±20.75	64.03±29.40	81.14±27.33
t test	1.59	1.60	1.17	0.29
P value	0.11	0.11	0.24	0.77
Family size:				
≤ 5 children (n=28)	57.14±35.33	93.92±12.71	72.32±26.35	81.54±28.45
> 5 children (n= 23)	67.39±22.87	90.86±16.28	66.66±28.09	84.05±29.18
t test	1.19	0.75	0.74	-0.31
P value	0.23	0.45	0.46	0.75
Hospital visits:				
≤ 3 times/ month (n=20)	69.08±28.07	94.75±6.97	71.66±27.49	78.75±29.67
>3 times / month (n=31)	50.41±31.35	91.12±17.54	68.54±27.10	85.21±27.94
t-test	2.16	0.87	0.39	-0.78
P value	0.03*	0.38	0.69	0.43
Type of therapy:				
Chemotherapy (n=45)	62.40±29.38	91.77±15.11	69.62±25.57	82.96±27.74
Radiotherapy (n=2)	87.50±17.67	95.00±0.00	87.50±5.89	1.00±0.00
Surgical (n=4)	41.66±41.94	1.00±0.00	62.50±47.87	70.83±43.30
F test	1.62	0.62	0.56	0.70
P value	0.20	0.54	0.57	0.49
Duration of diagnosis:				
≤ 6 months (n=24)	59.37±29.92	90.62±14.01	62.50±29.38	75.00±34.75
> 6 months (n=7)	91.66±10.75	98.57±3.77	75.00±26.78	97.61±6.29
≥ 1 year (n=20)	54.16±30.52	92.75±16.81	76.66±22.87	86.66±22.19
F test	4.64	0.82	1.69	2.11
P value	0.01*	0.44	0.19	0.13
Therapy duration:				
≤ 6 months (n=32)	62.50±29.78	92.65±12.76	65.62±27.98	77.86±32.35

> 6 months (n=5)	66.66±38.64	96.00±5.47	76.66±27.25	96.66±7.45
≥ 1 year (n=14)	58.33±31.35	91.07±19.72	76.78±24.49	88.69±21.08
F test	0.15	0.21	1.01	1.39
P value	0.85	0.80	0.37	0.25
Intensity of treatment:				
Low (n=28)	60.11±30.62	92.50±13.50	65.77±28.26	74.70±33.44
Medium (n=18)	63.42±32.35	91.11±17.45	73.61±28.04	91.20±19.06
High (n=5)	65.00±28.50	98.00±2.73	78.33±11.18	96.66±7.45
F test	0.09	0.44	0.73	2.66
P value	0.91	0.64	0.48	0.08
Treatment phase:				
On-treatment (n=30)	66.66±29.96	92.41±12.83	65.32±28.87	80.10±32.03
Follow-up (n=21)	54.16±30.52	92.75±16.81	76.66±22.87	86.66±22.19
t-test	1.44	-0.07	-1.48	-0.79
P value	0.15	0.93	0.14	0.42

265 ≤ = less than or equal to

> = More than

* = significant (p< 0.05)

266

267

268

269

Table 4: Binomial logistic regression showing predictors of health-related quality of life in study group.

270

271

	<u>Pain & Hurts</u>			<u>Nausea</u>			<u>Procedural Anxiety</u>			<u>Treatment Anxiety</u>		
	B	OR	P	B	OR	P	B	OR	P	B	OR	P
Gender:												
Male	2.06	7.85	.04*	.05	1.05	.94	-.47	.62	.49	-.97	.37	.16
Age at diagnosis time:												
<7 years	2.55	4.74	.04*	-1.02	.35	.14	.80	2.23	.21	.54	1.73	.39
Mother education:												
Educated	-1.20	.32	.28	-1.15	.315	.25	.64	1.90	.45	.67	1.96	.43
Hospital visits:												
> 3 time/m	.48	1.63	.54	.01	1.01	.98	.73	2.08	.24	.92	2.52	.14
Duration of diagnosis:												
> 1 year	2.18	8.87	.04*	.04	1.05	.95	-.78	.45	.33	.43	1.54	.59
Therapy duration:												
> 1year	-.25	.77	.87	-1.97	2.72	.99	.72	2.06	.59	.64	1.91	.63
Intensity of treatment:												
Low	.06	1.06	.97	.61	1.84	.69	-.34	.71	.80	.34	1.40	.79
Medium	-1.37	.25	.38	1.04	3.28	.03*	-.75	.47	.51	-.47	.62	.68

272 B= β coefficient

OR = odds ratio

P= p value

273

274

275

276

277

278

279

280 REFERENCES

- 281 1- Fawzy M, Saleh M, El-Wakil M, Monir Z, Eltahlawy E. Quality of Life in Egyptian
282 Children with Cancer. Journal of Cancer Therapy, 2013; 4, 1256-61.
283
- 284 2- Lins, MM, Santos MO, de Albuquerque PMFM, de Castro CCL, Mello MJG, de
285 Camargo B. Incidence and survival of childhood leukemia in Recife, Brazil: A
286 population-based analysis. Pediatric Blood & Cancer, 2016; 64 (8). doi:
287 10.1002/pbc.26391
- 288 3- CDC. United states cancer statistics:1999-2009 incidence and mortality web-based
289 report,2013. From www.cdc.gov/uscs.
- 290 4- National Cancer Research Institute (NICR). Cancer in Ireland 1994-2004: A
291 comprehensive report, 2005. Ireland.
- 292 5- Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z.
293 Cancer incidence and mortality in Iran. Ann Oncol, 2009. ;20(3):556-63.
- 294 6- Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MP, Kuehni CE, et
295 al.,. Incidence of childhood cancer in Switzerland: the Swiss childhood cancer registry.
296 Pediatr Blood Cancer, 2008; 50, 46-51.
- 297 7- Baade PD, Youlten DR, Valery PC, Hassall T, Ward L, Green AC, et al., . Trends in
298 incidence of childhood cancer in Australia, 1983-2006. Br J Cancer, 2010;102, 620-6.
- 299 8- Australasian Association of Cancer Registries (AACR A). Cancer in Australia: an
300 overview 2012. Canberra, 2012; AIHW. 74.
- 301 9- Wiangnon I, Veerakul G, Nuchprayoon I. Childhood cancer incidence and survival
302 2003-2005, Thailand: study from the Thai Pediatric Oncology Group. Asian Pac J
303 Cancer Prev,2011; 12, 2215-20.
- 304 10- Bahoush-Mehdiabadi G, Habibi R, Sharifabrizi A, Vossough P. Epidemiologic survey
305 of infantile cancer in Iran based on the data of the largest pediatric cancer referral
306 center (Ali- Asghar Children Hospital), 1996-2005. Asian Pac J Cancer Prev,2014; 15,
307 1211-7.
- 308 11- Hazarika M, Krishnatreya M, Bhuyan C , Saikia BJ , Katakia AC , Nandy P, et al., .
309 Overview of childhood cancers at a regional cancer centre in North-East India. Asian
310 Pac J Cancer Prev, 2014;15, 7817-9.

- 311 12- Al-Mutlaq HM, Bawazir AA, Jradi H , Al-Dhalaan ZA , Al-Shehri A. Patterns of
312 Childhood Cancer Incidence in Saudi Arabia (1999- 2008). *Asian Pacific Journal of*
313 *Cancer Prevention*,2015; 1 16, 431- 35.
- 314 13- Sung L, Klaassen RJ, Dix D, Pritchard S, Yanofsky R, Dzolganovski B, Almeida R,
315 Klassen A. “Identification of Pediatric Cancer Patients with Poor Quality of Life,”
316 *British Journal of Cancer*, 2009;100, (1): 82-88.
317
- 318 14- Chaudhry Z, Siddiqui S. “Health Related Quality of Life Assessment in Pakistani
319 Paediatric Cancer Patients Using PedsQL™ 4.0 Generic Core Scale and PedsQL™
320 Cancer Module,” *Health and Quality of Life Outcomes*,2012; 10: 52.
321
- 322 15- Varni JW, Seid M, Rode CA. *PedQL™ 4.0: Measurement Model for the Pediatric*
323 *Quality of Life Inventory™*. *Medical Care*,1999; 37: 126-39.
- 324 16- Eiser C, Eiser JR, Stride CB. Quality of life in children newly diagnosed with cancer
325 and their mothers. *Health and Quality of Life Outcomes*,2005; 3:29.
- 326 17- Varni JW, Burwinkle TM, Katz ER, Meeske K and Dickinson P. “The PedsQL in
327 Pediatric Cancer: Reliability and Validity of the Pediatric Quality of Life Inventory
328 Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module.
329 *Cancer*,2002; 94 (7): 2090-106.
- 330 18- Tanir MK, Kuguoglu S. Turkish validity and reliability of a Pediatric Quality of Life
331 cancer module for children aged 8-12 and parents. *Asian Pac J Cancer Prev*, 2011;
332 12:125-30.
- 333 19- Tsuji N, Kakee N, Ishida Y, Asami K, Tabuchi k, Nakadate H, et al. Validation of the
334 Japanese version of the Pediatric Quality of Life Inventory (PedsQL) cancer module.
335 *Health Qual Life Outcomes*,2011;9:22.
336
- 337 20- Magal-Vardi O, Laor N, Toren A, Strauss L, Wolmer L, Bielorai B, et al.
338 “Psychiatric Morbidity and Quality of Life in Children with Malignancies and Their
339 Parents,” *The Journal of Nervous and Mental Disease*, 2004; 92,872-75.
340
- 341 21- Landolt MA, Vollrath M, Niggli FK, Gnehm HE, Sennhauser EH. “Health-
342 Related Quality of Life in Children with Newly Diagnosed Cancer: A One Year
343 Follow-Up Study,” *Health and Quality of Life Outcomes*, 2006; 4 :63.
344
- 345 22- Ho PM, Bryson CL, Rumsfeld JS. “Medication Adherence: Its Importance in
346 Cardiovascular Outcomes,” *Circulation*,2009; 119 (23):3028-35.

347 23- Kurt BA, Nolan VG, Ness KK, Neglia JP, Tersak JM, Hudson MM, et al.
348 Hospitalization Rates among Survivors of Childhood Cancer in the Childhood
349 Cancer Survivor Study Cohort. *Pediatric Blood & Cancer*, 2012; 59 (1): 126-32.
350

351 24- Sitaresmi MN, Mostert S, Gundy CM, Sutaryo, Veerman AJP. "Health-Related
352 Quality of Life Assessment in Indonesian Childhood Acute Lymphoblastic Leu-
353 kemia," *Health and Quality of Life Outcomes*, 2008; 6(1): 96.
354

355 25- Ji Y, Chen S, Li K. "Measuring Health-Related Quality of Life in Children with
356 Cancer Living in Main- land China: Feasibility, Reliability and Validity of the
357 Chinese Mandarin Version of PedsQL 4.0 Generic Core Scales and 3.0 Cancer
358 Module," *Health and Quality of Life Outcomes*, 2011; 9: 103.
359

360 26- Huijjer HA, Sagherian K, Tamim H. Quality of life and symptom prevalence in
361 children with cancer in Lebanon: the perspective of parents. *Ann Palliat Med*, 2013;
362 2(2):59-70.
363

364 27- Tomlinson D, Hinds PS, Bartels U. Parent reports of quality of life for pediatric
365 patients with cancer with no realistic chance of cure. *J Clin Oncol*, 2011; 29:639-45.
366

367 28- C. R. Baggott CR, Dodd M, Kennedy C, Marina N, Matthay KK, Cooper B,
368 Miaskowski C. An Evaluation of the Factors that Affect the Health-Related Quality
369 of Life of Children Following Myelosuppressive Chemo- therapy. *Supportive Care*
370 *in Cancer*, 2011;19, 3, 353-361.
371

372 29- Pickard AS, Topfer LA, Feeny DH. A structured review of studies on
373 health-related quality of life and economic evaluation in pediatric acute
374 lymphoblastic leukemia. *J Natl Cancer Inst Monogr*, 2004; 33: 102–25
375
376
377
378
379
380
381
382